Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

NCT04306471 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Critical Limb Ischemia

Interventions

DRUG: Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
OTHER: Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months

Sponsor

Leonardo Clavijo

Collaborators

[object Object]